Alkem Laboratories Limited , a prominent player in the Indian pharmaceutical industry, has completed the transfer of its Trade Generics Business to its wholly-owned subsidiary, Alkem Wellness Limited, with a total consideration of ₹532.5 crores.

Business Transfer Completion

On December 30, 2025, the company announced the completion of the business transfer with the final payment of ₹32.5 crores from Alkem Wellness to the parent company. This brings the aggregate sale consideration to ₹532.5 crores under the Business Transfer Agreement.

Timeline of Events

The strategic restructuring process began with the initial intimation to stock exchanges on December 10, 2024. The Business Transfer Agreement was formally executed on September 26, 2025, setting October 1, 2025, as the effective date for the business transfer on a slump sale basis.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Manish Narang signed the regulatory filing, ensuring transparency for investors and stakeholders.

Strategic Impact

This restructuring move represents a significant step in streamlining Alkem Laboratories' operations. By transferring the Trade Generics Business to Alkem Wellness as a going concern, the company has created a more focused operational structure that could enhance resource allocation and operational efficiency across its business segments.

The completion of this ₹532.5 crore transaction marks a milestone in the company's strategic reorganization efforts, positioning both entities for optimized performance in their respective operational areas.

Alkem Laboratories has made headlines with two significant developments: a GST demand and the launch of a breakthrough cancer treatment.

GST Demand and Penalty

Alkem Laboratories has received a GST appeal order demanding Rs. 35.11 crore along with a penalty of Rs. 3.51 crore. The pharmaceutical company has announced its intention to contest this order, signaling a potential legal challenge ahead.

Innovative Treatment for HER2-Positive Breast Cancer

In a separate development, Alkem has launched Pertuza, a pertuzumab biosimilar, for HER2-positive breast cancer in India. This marks a crucial step towards improving accessibility and affordability of advanced cancer treatments in the country.

Pertuza, an injection of 420mg/14mL, is an indigenously-developed and manufactured biosimilar of pertuzumab. The drug has demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product in a pivotal phase 3 clinical trial conducted by Alkem's biotech subsidiary.

Addressing Accessibility Challenges

Dr. Vikas Gupta, Chief Executive Officer of Alkem, emphasized the importance of this launch, stating, "Breast cancer is the most common cancer among Indian women, and addressing its growing burden requires treatments that are effective, accessible and affordable." The company aims to make this critical therapy available to thousands of women each year who would otherwise be excluded due to cost barriers.

Strengthening Oncology Portfolio

The introduction of Pertuza further solidifies Alkem's position in the oncology sector. The company's growing portfolio includes other key products such as:

• Cetuximab biosimilar
• Denosumab biosimilar
• Bevacizumab biosimilar
• Romiplostim biosimilar

About Alkem Laboratories

Alkem Laboratories, with a 50-year legacy, stands as the fifth largest pharmaceutical company in the Indian market. The company boasts:

• 19 state-of-the-art manufacturing facilities
• Cutting-edge research and development (R&D) centers across India and the US
• A strong presence in therapy areas including anti-infectives, gastrointestinal, pain management drugs, and supplements
• A growing portfolio in chronic therapies such as diabetes, neurology, cardiology, dermatology, and urology

With the motto "Inspiring Healthier Lives," Alkem continues to reinforce its commitment to global health improvement through innovative and accessible medical solutions.

Financial Performance

In its latest quarterly results, Alkem Laboratories reported strong financial performance:

Despite the positive results, the company's shares ended 1% lower at ₹5,486.00 on the NSE.

The launch of Pertuza represents a significant step forward in Alkem's mission to combine scientific excellence with wider access to critical therapies, potentially benefiting numerous patients across India. However, the company now faces the challenge of addressing the GST demand while continuing its efforts in medical innovation and accessibility.